Nxera Pharma

4565 · TSE

Public Market Listing

4565TSE

TSE primary exchange listing

Live quotes, historical charts, and market capitalization for Nxera Pharma are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 3
Muscarinic M4 receptorSmall molecule
Schizophrenia

Upcoming events

(5 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
October 2027 (1)
DireclidinePhase 3Schizophrenia
Est. primary completion 2027-10 · NCT06963034 · CT.gov ↗
What to watch
November 2027 (1)
DireclidinePhase 3Schizophrenia
Est. primary completion 2027-11 · NCT07105098 · CT.gov ↗
What to watch
2028 (1)
February 2028 (1)
DireclidinePhase 2Bipolar I Disorder, Mania
Est. primary completion 2028-02 · NCT07288320 · CT.gov ↗
What to watch
2029 (1)
July 2029 (1)
DireclidinePhase 3Schizophrenia
Est. primary completion 2029-07 · NCT07227818 · CT.gov ↗
What to watch
2031 (1)
December 2031 (1)
DireclidinePhase 3Schizophrenia
Est. primary completion 2031-12 · NCT07114874 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

28 May 2025Topline resultDireclidinePhase 2 schizophrenia study results

Financial reports

No financial reports recorded.